ProxyMiner / Company

BOSTON SCIENTIFIC CORPBSX

Latest proxy: 2026 · view on SEC ↗ · CIK 0000885725

CEO total pay

$23,532,050

Michael F. Mahoney · 2025

Say on pay

9%

Latest disclosed shareholder vote

CEO pay ratio

Item 402(u)

348 to 1

Median employee: $23,532,050

Compensation committee

CD&A

Compensation Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Michael F. Mahoney2025 compensation
Chairman of the Board,President andChief Executive Officer
$23,532,050 10%
93% at-risk
$1,442,603$13,608,056$4,002,001$287,799
Daniel J. Brennan2025 compensation
Former Executive Vice President and Chief Financial Officer
$6,282,896 6%
89% at-risk
$660,990$3,447,272$1,098,004$36,738
Joseph M. Fitzgerald2025 compensation
Executive Vice President and Group President,Cardiovascular
$8,042,997 27%
88% at-risk
$892,604$4,309,282$1,458,001$45,657
Arthur C. Butcher2025 compensation
Executive Vice Presidentand Group President, MedSurg and Asia Pacific
$6,534,719 30%
85% at-risk
$744,822$3,447,272$1,012,501$219,667
Jonathan R. Monson2025 compensation
Named executive officer
$6,083,679
85% at-risk
$591,848$1,624,898$840,000$38,453
Jeffrey B. Mirviss2025 compensation
Executive Vice Presidentand President, PeripheralInterventions
$4,159,959 3%
81% at-risk
$702,042$1,995,566$793,126$59,238
Vance R. Brown2025 compensation
Named executive officer
$3,920,644
81% at-risk
$659,086$1,723,636$897,751$45,286

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

This Compensation Discussion & Analysis section describes material elements of our 2025 compensation program for our named executive officers (NEOs), who are our Chief Executive Officer (CEO), our Chief Financial Officer (CFO), and our three other most highly compensated executive officers, as well as our former chief financial officer and one other former executive officer who each retired during fiscal 2025. NEOs for the year ended December 31, 2025 are as follows: Michael F. MahoneyChairman of the Board, President and Chief Executive OfficerJonathan R. Monson(1)Executive Vice President and Chief Financial OfficerVance R. BrownExecutive Vice President, General Counsel and Corporate SecretaryArthur C. ButcherExecutive Vice President and Group President, MedSurg and Asia PacificJoseph M. FitzgeraldExecutive Vice President and Group President, CardiovascularDaniel J. Brennan(2)Former Executive Vice President and Chief Financial OfficerJeffrey B. Mirviss(3)Former Executive Vice President and President, Peripheral Interventions (1)Mr. Monson became Executive Vice President and CFO of the Company effective as of June 30, 2025. (2)Effective June 29, 2025, Mr. Brennan retired from his ro

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    Prohibition on Pledging and Hedging the Economic Value of Our Common Stock

  • pledging

    prohibited

    Prohibition on Pledging and Hedging the Economic Value of Our Common Stock

  • clawback

    present

    Clawback Policy provides for the mandatory recoupment of erroneously awarded incentive-based compensation in the event of an accounting restatement

  • stock ownership guidelines

    present

    Stock Ownership Guidelines

  • change in control

    Change in Control Agreements

    Change in Control Agreements

  • compensation consultant

    independent

    engages an independent compensation consultant, Semler Brossy Consulting Group, LLC (Semler Brossy), which serves under its direction and supervision

  • compensation committee

    Compensation Committee

    Chief Executive Officer and Compensation Committee Judgment

Performance markers

Metric facts

  • revenue

    $19.027 billion

    based on performance towards employee engagement and environmental goals, and in the case of the quality modifier, the distribution percentage may be reduced based on the Compensation Committee’s assessment of the Compan

  • operating income

    $19.931 billion

    value. 2026 Proxy Statement49 Results for 2025 ABP and Long-Term Incentive Plans Below is a summary of our 2025 results for the financial metrics in the Company’s short- and long-term incentive plans. ABP Financial Metri

  • annual incentive payout

    75%

    We maintain a Deferred Bonus Plan for certain of our management, including our NEOs, in order to provide them with the opportunity to defer up to 75% of their annual award under our ABP until the earlier of termination o

  • performance equity mix

    200%

    Company Performance-Based RSUs — Results for Performance Period ended December 31, 2025

  • say on pay

    9%

    Say on Pay Results202591.9%202492.7%202392.6%

  • ceo pay ratio

    348 to 1

    our methodology and the resulting CEO Pay Ratio. For 2025, our last completed fiscal year: •the annual total compensation of the employee identified at median of our Company (other than our CEO), was $67,539; and •the an

  • median employee compensation

    $23,532,050

    the annual total compensation of the employee identified at median of our Company (other than our CEO), was $67,539; and •the annual total compensation of our CEO was $23,532,050. Based on this information, for 2025, the

Ask

Anything about BOSTON SCIENTIFIC CORP’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…